Literature DB >> 33515643

Maternal immune activation and repeated maternal separation alter offspring conditioned avoidance response learning and antipsychotic response in male rats.

Shinnyi Chou1, Collin Davis2, Ming Li3.   

Abstract

Previous work shows that repeated administration of several commonly used antipsychotic drugs, such as olanzapine (OLZ) over several days, induces an enhanced disruption of conditioned avoidance response (CAR) (termed antipsychotic sensitization) in normal adolescent and adult rats. However, it is unclear whether the same phenomenon can also be demonstrated in rat models of schizophrenia. The present study investigated OLZ sensitization in a combined maternal immune activation (MIA) and repeated maternal separation (RMS) model of schizophrenia. Sprague-Dawley male rats were first subjected to an early prenatal exposure to polyinosinic:polycytidylic acid (PolyI:C) on gestation days 13 (4 mg/kg, iv) and 15 (6 mg/kg, iv). They were then repeatedly separated from their mothers for 3 h daily during the first two weeks of postpartum. After they became adolescent (on postnatal day, PND 43), acute and OLZ sensitization effects in the CAR model was assessed. Adolescent MIA rats showed an impaired acquisition of conditioned avoidance response, but displayed a normal acute OLZ-induced avoidance suppression and OLZ sensitization effect. In adulthood (PND 81), MIA rats again showed an impairment in the acquisition of CAR. However, they showed a reduced response to OLZ (1.0 mg/kg; sc) treatment during the repeated drug test days, indicating a disruption of the induction of OLZ sensitization. In the OLZ sensitization challenge test, both MIA and control rats exhibited a robust and similar sensitization effect. In both adolescence and adulthood, RMS alone had no effect on any of the behavioral outcomes, and combined MIA-RMS even abolished the MIA alone-induced disruption of avoidance acquisition and the induction of OLZ sensitization. These results indicate that MIA disrupts associative learning and may reduce antipsychotic efficacy in the early stage of OLZ treatment. RMS does not appear to affect associative learning and behavioral responses to OLZ, and may possibly attenuate MIA-induced deficits. Our findings demonstrate that OLZ sensitization is a robust phenomenon but its magnitude can be altered by early MIA.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Adolescent; Adult; Conditioned avoidance response; Maternal immune activation; Olanzapine; Repeated maternal separation

Mesh:

Substances:

Year:  2021        PMID: 33515643      PMCID: PMC7902402          DOI: 10.1016/j.bbr.2021.113145

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  45 in total

Review 1.  Long-term behavioral and neuroendocrine adaptations to adverse early experience.

Authors:  C O Ladd; R L Huot; K V Thrivikraman; C B Nemeroff; M J Meaney; P M Plotsky
Journal:  Prog Brain Res       Date:  2000       Impact factor: 2.453

2.  Adolescent olanzapine sensitization is correlated with hippocampal stem cell proliferation in a maternal immune activation rat model of schizophrenia.

Authors:  Shinnyi Chou; Sean Jones; Ming Li
Journal:  Brain Res       Date:  2015-06-03       Impact factor: 3.252

Review 3.  The effects of prenatal and postnatal environmental interaction: prenatal environmental adaptation hypothesis.

Authors:  Young-A Lee; Yukiori Goto
Journal:  J Physiol Paris       Date:  2013-04-25

4.  Parametric studies of antipsychotic-induced sensitization in the conditioned avoidance response model: roles of number of drug exposure, drug dose, and test-retest interval.

Authors:  Natashia Swalve; Ming Li
Journal:  Behav Pharmacol       Date:  2012-08       Impact factor: 2.293

5.  Repeated effects of the neurotensin receptor agonist PD149163 in three animal tests of antipsychotic activity: assessing for tolerance and cross-tolerance to clozapine.

Authors:  Shinnyi Chou; Collin Davis; Sean Jones; Ming Li
Journal:  Pharmacol Biochem Behav       Date:  2014-11-26       Impact factor: 3.533

6.  The time of prenatal immune challenge determines the specificity of inflammation-mediated brain and behavioral pathology.

Authors:  Urs Meyer; Myriel Nyffeler; Andrea Engler; Adrian Urwyler; Manfred Schedlowski; Irene Knuesel; Benjamin K Yee; Joram Feldon
Journal:  J Neurosci       Date:  2006-05-03       Impact factor: 6.167

7.  Stress in puberty unmasks latent neuropathological consequences of prenatal immune activation in mice.

Authors:  Sandra Giovanoli; Harald Engler; Andrea Engler; Juliet Richetto; Mareike Voget; Roman Willi; Christine Winter; Marco A Riva; Preben B Mortensen; Joram Feldon; Manfred Schedlowski; Urs Meyer
Journal:  Science       Date:  2013-03-01       Impact factor: 47.728

8.  Early sexual abuse and clinical depression in adult life.

Authors:  A Bifulco; G W Brown; Z Adler
Journal:  Br J Psychiatry       Date:  1991-07       Impact factor: 9.319

9.  Post-pubertal emergence of disrupted latent inhibition following prenatal immune activation.

Authors:  Lee Zuckerman; Ina Weiner
Journal:  Psychopharmacology (Berl)       Date:  2003-05-14       Impact factor: 4.530

10.  Chronic clozapine treatment improves prenatal infection-induced working memory deficits without influencing adult hippocampal neurogenesis.

Authors:  Urs Meyer; Irene Knuesel; Myriel Nyffeler; Joram Feldon
Journal:  Psychopharmacology (Berl)       Date:  2009-12-30       Impact factor: 4.530

View more
  1 in total

1.  Neuroprotective Effects of Phytochemicals against Aluminum Chloride-Induced Alzheimer's Disease through ApoE4/LRP1, Wnt3/β-Catenin/GSK3β, and TLR4/NLRP3 Pathways with Physical and Mental Activities in a Rat Model.

Authors:  Ahmed Mohsen Elsaid Hamdan; Fatimah Hussain J Alharthi; Ahmed Hadi Alanazi; Soad Z El-Emam; Sameh S Zaghlool; Kamel Metwally; Sana Abdulaziz Albalawi; Yahia S Abdu; Reda El-Sayed Mansour; Hoda A Salem; Zakaria Y Abd Elmageed; Karema Abu-Elfotuh
Journal:  Pharmaceuticals (Basel)       Date:  2022-08-17
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.